Literature DB >> 24721335

Three new players in energy regulation: preptin, adropin and irisin.

Suleyman Aydin1.   

Abstract

Homeostasis of energy is regulated by genetic factors, food intake, and energy expenditure. When energy input is greater than expenditure, the balance is positive, which can lead to weight gain and obesity. When the balance is negative, weight is lost. Regulation of this homeostasis is multi-factorial, involving many orexigenic (appetite-stimulating) and anorexigenic (appetite-suppressing) peptide hormones. Peripheral tissues are now known to be involved in weight regulation and research on its endocrine characteristics proceeds apace. Preptin with 34 amino acids (MW 3948 Da), adropin with 43 amino acids and a molecular weight of (4999 Da), and irisin with 112 amino acids (12587 Da), are three newly discovered peptides critical for regulating energy metabolism. Preptin is synthesized primarily in pancreatic beta cells, and adropin mainly in the liver and brain, and many peripheral tissues. Irisin, however, is synthesized principally in the heart muscle, along with peripheral tissues, including salivary glands, kidney and liver. The prime functions of preptin and adropin include regulating carbohydrate, lipid and protein metabolisms by moderating glucose-mediated insulin release. Irisin is an anti-obesitic and anti-diabetic hormone regulating adipose tissue metabolism and glucose homeostasis by converting white to brown adipose tissue. This review offers a historical account of these discovery and function of these peptides, including their structure, and physiological and biochemical properties. Their roles in energy regulation will be discussed. Their measurement in biological fluids will be considered, which will lead to further discussion of their possible clinical value.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adropin; Energy regulation; Irisin; Preptin

Mesh:

Substances:

Year:  2014        PMID: 24721335     DOI: 10.1016/j.peptides.2014.03.021

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  56 in total

1.  Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma.

Authors:  Niraj Nathan; Rachel W Kuchtey
Journal:  Curr Ophthalmol Rep       Date:  2016-10-11

2.  Comprehensive evaluation of irisin levels in fetomaternal circulation of pregnant women with obesity or gestational diabetes mellitus.

Authors:  Ali Seven; Esin Yalinbas; Suna Kabil Kucur; Emel Kocak; Ozben Isiklar; Beril Yuksel; Hakan Timur; Mehmet Erbakirci; Nadi Keskin
Journal:  Ir J Med Sci       Date:  2019-05-17       Impact factor: 1.568

3.  Irisin Levels Are not Associated to Resistance Training-Induced Alterations in Body Mass Composition in Older Untrained Women with and without Obesity.

Authors:  R A Tibana; D da Cunha Nascimento; N M Frade de Souza; V C de Souza; I V de Sousa Neto; F A Voltarelli; G B Pereira; J W Navalta; J Prestes
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

4.  Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects.

Authors:  Somaye Yosaee; Mahmoud Khodadost; Alireza Esteghamati; John R Speakman; Farzad Shidfar; Mahdiyeh Nasab Nazari; Vida Bitarafan; Kurosh Djafarian
Journal:  Am J Mens Health       Date:  2016-08-22

5.  Inverse association between carbohydrate consumption and plasma adropin concentrations in humans.

Authors:  Joseph R Stevens; Monica L Kearney; Marie-Pierre St-Onge; Kimber L Stanhope; Peter J Havel; Jill A Kanaley; John P Thyfault; Edward P Weiss; Andrew A Butler
Journal:  Obesity (Silver Spring)       Date:  2016-08       Impact factor: 5.002

6.  Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis.

Authors:  Z A Uc; S Gorar; S Mizrak; S Gullu
Journal:  J Endocrinol Invest       Date:  2018-05-18       Impact factor: 4.256

7.  Serum Irisin, Adropin, and Preptin in Obese Patients 6 Months After Bariatric Surgery.

Authors:  M Glück; J Glück; M Wiewióra; B Rogala; J Piecuch
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

8.  Evaluation of salusin-α and salusin-β levels in patients with type 2 diabetes mellitus and determination of the impact of severity of hyperglycemia on salusin levels.

Authors:  Derya Argun; Ferit Argun; Betul Borku Uysal
Journal:  Ir J Med Sci       Date:  2021-06-09       Impact factor: 1.568

9.  Adropin-based dual treatment enhances the therapeutic potential of mesenchymal stem cells in rat myocardial infarction.

Authors:  HuiYa Li; DanQing Hu; Guilin Chen; DeDong Zheng; ShuMei Li; YunLing Lin; HuaShan Hong; Yukun Luo; YiLang Ke; Yu Huang; LingZhen Wu; TingXiang Lan; WenYing Wang; Jun Fang
Journal:  Cell Death Dis       Date:  2021-05-18       Impact factor: 8.469

Review 10.  Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Authors:  Surojit Paul; Eduardo Candelario-Jalil
Journal:  Exp Neurol       Date:  2020-11-02       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.